Posted on October 18th, 201910/18/19
Providers order unnecessary tests for a variety of reasons: pressure from patients, fears of malpractice suit, not being knowledgeable about current “best” practices as well as for potential financial advantage for them or their health system. Clinical pathways built on solid clinical guidelines have the potential to lower costs through reduced resource utilization of potentially, […]
Posted on October 17th, 201910/17/19
Healthcare leaders often talk about ensuring that the right patient receives the right medication at the right time. On its face, this concept seems straightforward. We know that different patients respond differently to different therapies, such that we cannot consistently replicate randomized clinical trial experience in the real world. Thus, healthcare providers (HCPs) must make […]
Posted on September 17th, 20199/17/19
A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]
Posted on September 17th, 20199/17/19
Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we see pockets of transformation. The problem is exactly that – “pockets” of transformation. Your product launch strategy has to […]
Posted on September 17th, 20199/17/19
Market Access Macrotrends provides insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in the access environment related to: • Current and emerging U.S. access trends • Response by stakeholders to market access […]
Posted on September 13th, 20199/13/19
With more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease, regenerative medicine holds the hope for a cure – transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. With the advancement of new technologies coupled with the creation of new […]
Posted on September 13th, 20199/13/19
The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to market, but how do brands keep their products positioned appropriately with limited resources, data and time? EVERSANA’s Executive Vice […]
Posted on September 9th, 20199/9/19
Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has also become notoriously difficult to manage for the more than 600 pharmaceutical companies enrolled. Data validity, crossover between lines of business, and conflicting regulations each […]
Posted on August 26th, 20198/26/19
As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and reimbursement. While it is certain that clinical pathways are shaping and will continue to shape health care regardless of system, what is far […]
Posted on August 26th, 20198/26/19
Insurance and Benefits Design provides insight on changes in insurance and benefit design in the next three years so you can anticipate the evolving access opportunities and risks for your company’s brands. Insurance and Benefit Design answers your questions about changes in the access environment related to: • Macrotrends • Benefit design and drug management […]
